The filing is administrative (reverse split adjustment), but the embedded financials show a pre-revenue biotech with a rapidly shrinking cash runway and no near-term catalyst to reverse the trend. The $1M market cap already prices in extreme distress, but the going-concern warning and accelerating cash burn suggest further dilution or restructuring is imminent. Monitor for additional equity offerings or a potential Nasdaq delisting if the stock price fails to maintain compliance post-split.
Price Chart
Executive Summary
Silexion Therapeutics filed an 8-K to update its 2025 annual and Q1 2026 interim financial statements to reflect a 1-for-10 reverse share split effective May 28, 2026. The filings confirm a going-concern qualification from the auditor, with cash burn accelerating: cash dropped from $5.99M at Dec 2025 to $2.41M at Mar 2026, and operating cash outflow was $3.65M in Q1 2026 alone. The company has no revenue, a net loss of $2.73M in Q1 2026, and management states current funds cover only 'several months' of operations. This is a routine administrative filing to adjust share data, but the underlying financial deterioration and cash runway risk are severe for a $1M market cap stock.
Key Facts
- Auditor's report includes a going-concern qualification; management states funds sufficient for 'only several months' from the issuance date of the financial statements.
- Cash and cash equivalents fell from $5.99M at Dec 31, 2025 to $2.41M at Mar 31, 2026, a 60% decline in three months.
- Operating cash outflow was $3.65M in Q1 2026, up from $2.45M in Q1 2025, indicating accelerating cash burn.
- Net loss for Q1 2026 was $2.73M, compared to $1.74M in Q1 2025, a 57% increase in quarterly losses.
- The company has no revenue and is a clinical-stage biotech developing RNAi therapies for KRAS-driven cancers.
- A 1-for-10 reverse share split was effected on May 28, 2026, and the financial statements were retroactively adjusted.
- Subsequent to Q1 2026, the company raised ~$1.0M net from a warrant exercise inducement in May 2026 and ~$1.1M from ATM sales in April-May 2026.
- Shareholders' equity collapsed from $2.60M at Dec 31, 2025 to just $0.29M at Mar 31, 2026.
Financial Impact
Cash burn of $3.65M in Q1 2026; cash runway of only several months from the financial statement issuance date (March 2026 for the annual, May 2026 for the interim).
Risk Factors
- Going-concern risk is explicit and severe; cash runway measured in months.
- Massive dilution risk: 309,868 warrants outstanding as of Dec 31, 2025, plus subsequent ATM sales and warrant exercises, all over a tiny existing share base.
- Nasdaq continued listing risk: the reverse split may not be sufficient to maintain the $1.00 bid price requirement given the stock's trajectory.
- No revenue and no approved products; clinical-stage pipeline (SIL204) has no disclosed near-term catalyst or data readout.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-004128 |
| Exhibit: exhibit_99-2.htm | 0001178913-26-004128 |
| Document: zk2635957.htm | 0001178913-26-004128 |
| Document: 0001178913-26-004128-index-headers.html | 0001178913-26-004128 |
| Document: 0001178913-26-004128-index.html | 0001178913-26-004128 |
| Document: 0001178913-26-004128.txt | 0001178913-26-004128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1657 (−7.74%) |
Oct 5, 2026 22d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1657 (+36.95%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1657 (−40.18%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1657 (+40.25%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 $0.1650 | ▲ +48.11% | ▲ +48.77% | $0.1657 (+47.89%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 $0.1657 | ▲ +47.96% | ▲ +48.67% | $0.1657 (+47.96%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1657 (+33.29%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1657 (+60.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers